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Abstract
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Objectives—Several studies have suggested the efflux transporter P-glycoprotein (P-gp) to play
a role in the etiology of Alzheimer's disease through the clearance of amyloid beta (Aβ) from the
brain. In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target
for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of Aβ, a
neuropathological hallmark of Alzheimer's disease.
Methods—Uptake studies for 125I-radiolabelled Aβ1–40, and fluorescent immunostaining
technique for P-gp and fluorescent imaging of Aβ1–40 were carried out in LS-180 cells following
treatment with drugs known to induce P-gp expression.
Key findings—Approximately 10–35% decrease in 125I-Aβ1–40 intracellular accumulation was
observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, βestradiol and pentylenetetrazole compared with control. Also, fluorescent micrographs showed an
inverse relationship between levels of P-gp expression and 5-carboxyfluorescein labelled Aβ
(FAM-Aβ1–40) intracellular accumulation. Quantitative analysis of the micrographs revealed that
the results were consistent with those of the uptake studies using 125I-Aβ1–40.

NIH-PA Author Manuscript

Conclusions—The investigated drugs were able to improve the efflux of Aβ1–40 from the cells
via P-gp up-regulation compared with control. Our results elucidate the importance of targeting
Aβ clearance via P-gp up-regulation, which will be effective in slowing or halting the progression
of Alzheimer's disease.
Keywords
Alzheimer's disease; beta amyloid; clearance; P-glycoprotein; up-regulation

Introduction
Alzheimer's disease, a major cause of dementia, is a significant health care problem with
about 5.3 million people currently affected in the USA. With the aging of the American
population, projections suggest that by 2025, about 12 million Americans will suffer from
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this disease.[1] Aging is considered the major risk factor of Alzheimer's disease, which is
characterized pathologically by the accumulation of tangles and senile plaques in the brain.
Senile plaques are composed of beta amyloid peptides (Aβ).[2]
Significant efforts have been made to elucidate the mechanisms responsible for Aβ
accumulation in the brain of Alzheimer's patients. Among such mechanisms is the increased
level of Aβ as a result of its faulty clearance across the blood–brain barrier (BBB).[3]
Continuous removal of Aβ from the CNS is important for preventing potentially neurotoxic
Aβ accumulation. P-glycoprotein (P-gp) has been reported to play a role in Aβ clearance at
the BBB.[4–6] Reduced expression of P-gp at the BBB has been observed during normal
aging and in Alzheimer's patients.[5,7]
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P-gp, the product of MDR1 gene, is perhaps the best-known and studied efflux transporter
which, under normal physiological conditions, is widely expressed in barrier and excretory
tissues.[8] P-gp is highly expressed on the luminal membrane of the endothelial cells at the
BBB.[9] At the BBB, P-gp serves as a defence mechanism against a wide spectrum of nonpolar therapeutic drugs and xenobiotics.[10] While its endogenous function is not fully
understood, the expression pattern of P-gp has recently been suggested to play a key role in
the etiology of Alzheimer's disease,[4] and has been shown to play substantial role in Aβ
levels in the brain.[4–6] In-vitro binding studies showed that efflux of Aβ1–40 is mediated by
P-gp as a result of direct interaction between Aβ and P-gp.[11] These results were confirmed
in cell culture experiments using MDR1-transfected polarized kidney epithelial cells (LLCPK1).[6] Moreover, when labelled Aβ1–40 protein was microinjected into the CNS of P-gp
knockout mice, the clearance rate of Aβ1–40 across the BBB was reduced to half compared
with the wild-type mice.[4]
With such a role of P-gp in the clearance of Aβ across the BBB, it is expected that a small
decline in its expression or activity, by aging or Alzheimer's disease, will result in decreased
clearance of Aβ from the brain, an increase in its level and consequent Aβ deposit. Thus, in
the current studies we have hypothesized that up-regulation of the Aβ efflux transporter, Pgp, will enhance Aβ clearance and decelerate its intracellular accumulation.
In a previous study, we have demonstrated an in-vitro concentration-dependent increase in
P-gp expression and activity by various drugs, including rifampicin, dexamethasone,
caffeine, verapamil, hyperforin, β-estradiol and pentylenetetrazole, and ranked these drugs
for their potencies to up-regulate P-gp (submitted). Subsequently, in the present study and to
demonstrate the possibility of P-gp as potential therapeutic target for Alzheimer's disease,
the impact of P-gp in-vitro up-regulation by the above drugs on Aβ cellular accumulation
has been investigated in LS-180 cells as a model cell line for the BBB.
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The results obtained from this study should furthermore establish the most promising modes
of intervention and contribute to drug discovery efforts aimed at selective up-regulation of
P-gp as a therapeutic approach for treatment or prevention of Alzheimer's disease.

Materials and Methods
Materials
LS-180 cell line and all cell culture reagents were obtained from American Type Culture
Collection (Manassas, USA). Rifampicin, dexamethasone, hyperforin, pentylenetetrazole,
caffeine, β-estradiol and verapamil were purchased from Sigma-Aldrich (St Louis, USA).
The reagents and supplements required for Western blotting were purchased from Bio-Rad
(Hercules, USA). The mouse monoclonal P-gp antibody (C-219) was obtained from
Covance Research Products (Dedham, USA). Anti-β-actin (C-11) and horseradish
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peroxidase (HRP)-labelled secondary antibodies were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, USA). Normal donkey serum, normal goat serum and
Rhodamine Red-X-conjugated AffiniPure donkey anti-mouse IgG (H + L) secondary
antibody against P-gp were purchased from Jackson ImmunoResearch Laboratories Inc.
(West Grove, USA). Synthetic 125I-Aβ1–40 (human) was purchased from PerkinElmer Inc.
(Waltham, USA). FAM-labelled Aβ1–40 was purchased from AnaSpec, Inc. (Fremont,
USA). All other reagents and supplies were purchased from VWR (West Chester, USA).
Cell culture
LS-180 cells were cultured in RPMI-1640 growth medium supplemented with 10% fetal
bovine serum (FBS), 50 IU/ml penicillin and 50 μg/ml streptomycin. The cells were grown
to confluence in 75-cm2 cell culture flasks for 3–6 days at 37°C/5% CO2 and used between
passage numbers 5–20.
Drug treatment of LS-180 for in-vitro induction study
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Induction of P-gp was carried out as follows. Cells were seeded in 10-mm cell culture dishes
at a density of 5 × 106 cells/dish and allowed to attach and grow up to 50–60% confluence.
Stock solutions of rifampicin, pentylenetetrazole, β-estradiol, dexamethasone, hyperforin,
verapamil and caffeine were diluted to a final concentration of 50 μM (hyperforin, 100 nM) in
growth medium before use. Forty-eight hours after cell seeding, control and drug-containing
media were added to the respective treatment cells. The cells were then incubated for 48 h at
37°C/5% CO2. The media were not renewed for the duration of the experiment.
Western blot analysis of P-gp
Cellular protein (16 μg) was resolved on 7.5% SDS-polyacrylamide gels and transferred
onto nitrocellulose membrane. The monoclonal antibody for P-gp (C-219) and β-actin
(C-11) at dilutions 1 : 200 and 1 : 3000, respectively, were used. For protein detection, the
membrane was incubated with HRP-labelled secondary IgG antibody for P-gp (anti-mouse)
and β-actin (anti-goat) at dilution 1 : 5000. The bands were visualized using Pierce
chemiluminescence detection kit (Thermo Scientific; Rockford, USA). Quantitative analysis
of the immunoreactive bands was performed using Syngene luminescent image analyzer
(Scientific Resources Southwest, Inc., Stafford, USA). Three independent Western blotting
experiments were carried out for each drug.
In-vitro uptake of 125I-Aβ1–40 in control and treated LS-180 cells
125I-Aβ
1–40
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was used after aqueous reconstitution according the manufacturer
recommendation to avoid the formation of Aβ1–40 oligomer aggregates. [12] 125I-Aβ1–40
uptake in control and treated LS-180 cells was investigated as follows. LS-180 cells were
cultured onto 48-well plates at 5 × 104 cells/well and treated with 50 μM of rifampicin,
dexamethasone, caffeine, verapamil, β-estradiol, pentylenetetrazole or 100 nM of hyperforin,
as described above. The medium was aspirated and the cells were washed by incubation in
fresh growth medium for 4 h. The cells were washed, and then pre-incubated for 30 min
with or without 100 μM verapamil as a P-gp inhibitor in transport buffer (in mM: 141 NaCl, 4
KCl, 2.8 CaCl2, 1 MgSO4, 10 D-glucose and 10 HEPES). The activity experiments were
started by the addition of 250 nCi/ml of 125I-Aβ1–40 in transport buffer with or without 100
μM verapamil for 1.0 h at 37°C/5% CO2. The activity experiment was terminated by washing
the cells with ice-cold phosphate-buffered saline (PBS). Cells then were lysed for 1.0 h at
37°C. Intracellular radioactivity of 125I-Aβ1–40 was measured using Wallac 1470 Wizard
Gamma Counter (PerkinElmer Inc.), and the data were normalized for the protein content.
Intracellular accumulation of 125I-Aβ1–40 was expressed as percent of the means and
standard deviation for the amount of Aβ1–40 (nCi/mg protein) detected in treated cells
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compared with control cells, both in the presence and absence of verapamil. For each drug
three independent experiments were carried out with four replicates in each experiment.
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Immunofluorescence staining of P-gp and fluorescence imaging of FAM-Aβ1–40
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To confirm the effect of drug treatment on P-gp and the consequent intracellular
accumulation levels of Aβ, both protein and peptide expressions were visualized using
confocal microscopy following treatment with selected drugs, including rifampicin, caffeine,
verapamil and β-estradiol. LS-180 cells (5 × 104) were seeded on 35-mm poly-d-lysinecoated glass bottom plates (MatTek Corporation, Ashland, USA) and treated with 50 μM of
rifampicin, caffeine, verapamil or β-estradiol as described above. After 48 h, the cells were
washed with PBS and incubated with 500 nM of FAM-labelled Aβ1–40 in serum-free medium
for 1.0 h. The cells were then washed with PBS, fixed with 4% formaldehyde and blocked
with 10% of normal donkey and goat sera. This step was followed by overnight incubation
at 4°C with a 1 : 50 dilution of primary antibody against P-gp in solution composed of 1%
normal donkey and goat sera in PBS. The cells were washed with PBS and incubated for 30
min with Rhodamine Red goat anti-mouse secondary antibody at 1 : 250 dilution. Images for
P-gp and Aβ were captured using Leica TCS-SP5 inverted confocal microscope equipped
with 488 nm line of Argon Laser (Leica Microsystems Inc., Bannockburn, USA). Negative
controls for each treatment that were processed without primary antibody showed negligible
background fluorescence (data not shown). P-gp and Aβ1–40 membrane fluorescence for
each sample were quantified using ImageJ version 1.44 software (Research Services Branch,
NIMH/NIH, Bethesda, USA). This experiment was repeated three times.
Statistical analysis
Wherever possible, the experimental results were statistically analysed for significant
difference using two-tailed Student's t-test to evaluate differences between controls and
treated groups. P < 0.05 was considered to be statistically significant.

Results
In-vitro induction of P-gp expression
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The ability of the investigated drugs to induce P-gp expression was assessed by Western
blotting using the C-219 antibody. Figure 1a–1e illustrates the fold increase in P-gp
expression obtained following Western blotting in LS-180 cells treated with 50 μM of
rifampicin, dexamethasone, caffeine, verapamil or 100 nM hyperforin, and quantified by
densitometry of the immunoblots. In addition, and as a representative drug, Figure 1f
illustrates a dose-dependent increase in P-gp expression and activity as a result of verapamil
treatment. All investigated drugs resulted in an increase in P-gp expression following 48 h
treatment to different extents. Under the in-vitro cell culture conditions, a 2.7-fold increase
in the expression of P-gp protein was observed post-incubation with verapamil while
rifampicin increased P-gp expression by 5.6 fold compared with control. Hyperforin showed
up to 2.6-fold increase at 100 nM. Other investigated drugs, including dexamethasone and
caffeine, resulted in up-regulation of P-gp expression by 70% and 30%, respectively, when
compared with control, while pentylenetetrazole and β-estradiol increased P-gp expression
only by 10%.
Effect of P-gp up-regulation on 125I-Aβ1–40 cellular uptake in vitro
To determine the consequence of P-gp up-regulation on the accumulation of Aβ1–40, the
cellular uptake of radiolabelled 125I-Aβ1–40 was evaluated following drug treatment in the
presence and absence of 100 μM verapamil, a specific P-gp inhibitor. Figure 2 shows the
percentage change in the intracellular accumulation of Aβ1–40 with and without verapamil in
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treated LS-180 cells compared with control. As a result of P-gp up-regulation by the drugs,
the cellular accumulation of Aβ1–40 has decreased, and the inhibition of P-gp by verapamil
enhanced Aβ1–40 accumulation confirming the specific role of P-gp on Aβ1–40 cellular
uptake. This difference in Aβ1–40 was more apparent and statistically significant (P < 0.05)
in cells treated with caffeine, rifampicin, verapamil, β-estradiol and 100 nM hyperforin,
which resulted in 15–35% decrease in Aβ1–40 cellular uptake (Figure 2). When LS-180 cells
treated with these five drugs were co-incubated with verapamil and 125I-Aβ1–40, a
significant increase in 125I-Aβ1–40 uptake by 16–32% was observed (P < 0.05). On the other
hand, cells treated with dexamethasone and pentylenetetrazole showed moderate decrease
in 125I-Aβ1–40 cellular uptake by approximately 10%, and their co-incubation with
verapamil increased its intracellular uptake by 8–12%. The above results confirm the role of
P-gp in determining Aβ1–40 intracellular levels. The induction of P-gp lowered Aβ1–40
cellular uptake by enhancing its clearance, while the inhibition of P-gp increased Aβ1–40
uptake.
Effect of P-gp up-regulation on the intracellular fluorescence intensity of FAM-Aβ1–40
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Figure 3a–3c show representative fluorescent micrograph images of P-gp expression of
untreated (control, Figure 3a), rifampicin-treated (Figure 3b) and caffeine-treated (Figure
3c) cells captured by TCS-SP5 Leica confocal microscope. Fluorescence of secondary
antibody against P-gp was located mainly on the cell membrane, while the fluorescence
associated with FAM-Aβ1–40 was taken up into the cells (Figure 3d–3f). The conjugation of
Aβ peptide with FAM fluorophore did not affect the structure and function of the peptide,
and the in-vitro uptake of labelled and unlabelled Aβ by cells was similar.[13]
Quantitative analysis of P-gp expressed in LS-180 cells showed significant increase in
membrane P-gp expression of drug-treated LS-180 compared with control. For example,
rifampicin and caffeine resulted in 6.2-fold and 1.5-fold increase, respectively, in P-gp
expression compared with control (P < 0.05; Figure 3, top bar graph). These results are in
agreement with those obtained from Western blotting data (Figure 1). At the same time, this
increase in P-gp expression caused by both drugs was accompanied by 43–67% decrease in
the intracellular accumulation of FAM-Aβ1–40 when compared with control (P < 0.05;
Figures 3d–3f, bottom bar graph). In addition, treatment with β-estradiol and verapamil
decreased the intracellular accumulation of FAM-Aβ1–40 by 28% and 59%, respectively.

Discussion
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There is compelling evidence that Aβ protein aggregation is an essential early event in
Alzheimer's disease pathogenesis.[2] In fact, upon aging, human brain inevitably starts to
accumulate Aβ suggesting that the Alzheimer's disease cascade is initiated as a normal
consequence of the aging process. However, as compared with healthy aged brains, the
accumulation of neurotoxic Aβ in the brains of Alzheimer's patients, although starting
slowly, begins to accelerate exponentially after a certain point.[14] This implies that a slight
increase in the steady state of Aβ above normal in the brain of Alzheimer's patients may
initiate one or multiple vicious processes causing dramatic increase in Aβ levels.[14]
LS-180, a human colon adenocarcinoma cell line,[15] is a well characterized in-vitro model
utilized in P-gp efflux studies. LS-180 cell line endogenously expresses P-gp and pregnaneX-receptor (PXR), which controls expression of P-gp.[16,17] As a result, this cell line is
considered a useful tool for the mechanistic investigation of P-gp substrates and is
frequently utilized to investigate the effect of P-gp modulation by inhibition or up-regulation
on the uptake or clearance of substrate drugs.[18] As most drugs investigated, including
rifampicin, dexamethasone, verapamil and hyperforin, have been reported to up-regulate Pgp by activating PXR,[19–22] in the current study LS-180 cell line was chosen as a model for
J Pharm Pharmacol. Author manuscript; available in PMC 2012 August 1.
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the BBB to evaluate the effect of induced expression of P-gp caused by these drugs on the
increased efflux, or clearance, of Aβ, a P-gp substrate.
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Available experimental data strongly suggest impaired clearance of Aβ across the BBB
might largely contribute to the formation of Aβ brain deposits and Alzheimer's disease
progression. Also, it has been demonstrated that the efflux transporter P-gp plays a
substantial role in the elimination of Aβ1–40 and Aβ1–42 from the brain across the
BBB.[4–6,11] Accordingly, in this study we report the impact of P-gp up-regulation on the
intracellular accumulation of Aβ1–40 in vitro by rifampicin, dexamethasone, verapamil,
caffeine, pentylenetetrazole and β-estradiol at 50 μM, and hyperforin at 100 nM
concentrations. As both Aβ peptide species have been implicated in the pathogenesis of
Alzheimer's disease,[23] in this study Aβ1–40 was used to investigate our hypothesis.
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The examined drugs were particularly investigated as they demonstrated potency to upregulate P-gp expression and activity in a concentration-dependent manner (Figure 1f), and
these same drugs have been reported to have positive impact on Alzheimer's disease. For
example, in humans, a 3-month course of rifampicin (300 mg p.o.) and doxycycline
attenuated the rate of cognitive decline in patients with mild-to-moderate Alzheimer's
disease. The authors concluded that such efficacy was unrelated to the antibiotic activity of
either drug.[24] In addition, several studies showed caffeine intake as a protective factor for
Alzheimer's disease. In a case-controlled study conducted on 54 patients with probable
Alzheimer's disease,[25] results showed that patients with Alzheimer's disease had an
average daily caffeine intake of 73.9 ± 97.9 mg during the 20 years that preceded diagnosis
of Alzheimer's disease, whereas the controls had an average daily caffeine intake of 198.7 ±
135.7 mg during the corresponding 20 years of their lifetimes. Further, in-vivo studies on
mice models of Alzheimer's disease confirmed caffeine's protective role against cognitive
impairment and showed that it reduced brain and plasma levels of Aβ1–40.[26,27] Similar
positive effects have been reported with hyperforin, which reduced amyloid deposit
formation in rats injected with amyloid fibrils in the hippocampus, prevented Aβ-induced
neurotoxicity and improved spatial learning acquisition.[28]
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Pentylenetetrazole,[29] β-estradiol,[30] verapamil[31] and dexamethasone[32] have also shown
anti-Alzheimer's effects in human or animal Alzheimer's disease models. For example,
pentylenetetrazole, an old drug once used to treat epilepsy, has been shown to up-regulate Pgp at the BBB of rats treated with 30 mg/kg for 24 days, where P-gp levels in the brain
increased by 1.7-fold.[33] When pentylenetetrazole (3 mg/kg, a non-epileptic dose) was
administered to a mouse model with Down's syndrome symptoms, Ts65Dn, for 17 days,
pentylenetetrazole substantially improved learning and memory in these mice.[29] Ts65Dn
mice demonstrate increased levels of Aβ in the hippocampus and astrocytic hypertrophy.[29]
Collectively, the above summarized data highlight the possible link between the induction of
P-gp by the investigated drugs and their associated decreasing risk or protection against
Alzheimer's disease. Consequently, in this study we have investigated the hypothesis that Pgp up-regulation enhances Aβ clearance and decelerates Aβ deposition, thus providing
effective therapeutic strategy in slowing or halting the progression of Alzheimer's disease.
We have shown that exposure of LS-180 cells to rifampicin, verapamil, hyperforin, caffeine,
β-estradiol and, to a lesser extent, pentylenetetrazole and dexamethasone resulted in an
increase in P-gp expression ranging from 10 to 460%, and a subsequent decrease in Aβ1–40
cellular uptake ranging from 10 to 35%. In addition, P-gp inhibition by verapamil following
its up-regulation by the investigated drugs enhanced Aβ1–40 cellular uptake by 8–32%.
Verapamil has been reported to be a specific competitive inhibitor for P-gp and is commonly
used to evaluate the functionality of the P-gp efflux transporter.[34,35]
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The above results confirm that decreased intracellular accumulation of Aβ1–40 is associated
with P-gp up-regulation caused by the drugs. The investigated drugs demonstrated different
potencies in up-regulating P-gp expression (Figure 1). Most of the drugs evaluated in this
study up-regulate P-gp via PXR activation,[19–22] where, following drug binding, PXR
forms a heterodimer with the retinoid X receptor (RXR) and subsequently binds to PXR
response elements in the 5′-flanking region of the MDR1 gene resulting in transcriptional
activation.[36] PXR activation is drug dependent,[36] which may explain the variability in
drugs potencies to up-regulate P-gp. Nonetheless, these results support the role of such drugs
in enhancing Aβ clearance as a result of P-gp up-regulation at the BBB, reducing its brain
levels and thus improving cognitive function and preventing Aβ-induced neurotoxicity.
Furthermore, these findings support our hypothesis that targeting P-gp at the BBB as a
therapeutic strategy will be beneficial for patients with Alzheimer's disease.
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In addition, the results from expression studies of P-gp by confocal microscopy, while
somewhat higher, were consistent with those of the uptake studies using radiolabelled 125IAβ1–40, confirming the inverse relationship between P-gp expression and Aβ1–40
intracellular accumulation. Images of LS-180 cells demonstrated that rifampicin and
caffeine treatments increased P-gp expression by 6.2 and 1.5 fold, respectively. Such
increase in P-gp expression was associated with a decrease in FAM-Aβ1–40 by both drugs
when compared with control. However, the decrease in 125I-Aβ1–40 and FAM-Aβ1–40
accumulation in LS-180 cells treated with caffeine (35 and 67%, respectively) was higher
than in those treated with rifampicin (16 and 43%, respectively) despite the ~ 6.0-fold
increase in P-gp expression caused by rifampicin compared with the 1.5-fold increase by
caffeine. Possible explanations for this observation could be that the increase in P-gp
expression caused by rifampicin is not equivalently functional, or the presence of an
additional mechanism of Aβ1–40 transport across the membrane could be modulated by
either treatment. This information is currently under investigation in our laboratory.
Similarly, treatment of cells with β-estradiol and verapamil resulted in a significant decrease
in the cellular uptake of 125I-Aβ1–40 (15 and 22%, respectively) and FAM-Aβ1–40 (28 and
59%, respectively), while pentelenetetrazole and dexamethasone had a moderate effect on
both P-gp expression and 125I-Aβ cellular uptake. Overall, these results confirm the effect of
P-gp up-regulation in enhanced efflux, hence clearance, of Aβ from the cells. Further studies
are in progress to evaluate the above drugs in vivo and verify the consequences of such
induction on P-gp activity at the BBB and Aβ clearance.

Conclusions
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Our results showed that in-vitro treatment of LS-180 cells with rifampicin, caffeine,
verapamil, hyperforin and β-estradiol, and to a lesser extent pentylenetetrazole and
dexamethasone, resulted in significant decrease in the intracellular accumulation of Aβ1–40
compared with control as a result of P-gp up-regulation. In addition, the results support the
link between P-gp up-regulation caused by these drugs and cognitive improvement in
patients with Alzheimer's disease. Thus, targeting P-gp could be an effective strategy in
slowing or halting the progression of Alzheimer's disease.
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Figure 1.

Representative Western blot and densitometry analysis for the ratio of P-gp to β-actin
expression levels in LS-180 cells treated with (a) 50 μm caffeine (CAF) (b) 50 μm
dexamethasone (DEX) (c) 100 nm hyperforin (HYP) (d) 50 μm rifampicin (RIF) and (e) 50
μm verapamil (VER) compared with control (CTRL). (f) A representative figure for dose
dependent increase in P-gp expression (column bars) and activity (line) following treatment
with verapamil. The data are expressed as the mean + SD, n = 3 independent experiments.
*P ≤ 0.05 vs control.
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Figure 2.
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Effect of treatment of LS-180 cells with rifampicin (RIF), verapamil (VER), dexamethasone
(DEX), b-estradiol (EST), pentylenetetrazole (PTZ), hyperforin (HYP) and caffeine (CAF),
on the intracellular accumulation of radiolabelled 125I-Aβ1–40. Percent change in the
accumulation of Aβ1–40 was evaluated in the presence (dashed bars) and absence (solid bars)
of verapamil, a specific P-gp inhibitor. The data are expressed as mean ± SD, n = 3
independent experiments, each drug 4 replicate/experiment. *P < 0.05.
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Figure 3.

Representative fluorescent micrographs of P-gp (a, b and c) and FAM-Aβ1–40 (d, e and f) for
control (a and d) and treated LS-180 cells with rifampicin (b and e) and caffeine (c and f).
Quantitative folds change in the P-gp expression and FAM-Aβ1–40 intracellular
accumulation were measured using ImageJ version 1.44. The data are expressed as mean ±
SD, n = 3. *P < 0.05. Scale bar = 25 μm.
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